Fate Therapeutics Inc. CEO's Stock Sale for Tax Obligations

On August 4, 2025, Bahram Valamehr, President and CEO of Fate Therapeutics Inc., sold 14,466 shares of common stock at a weighted average price of $1.0643 per share. This sale was executed to cover tax withholding obligations related to the vesting of 25,000 shares of Common Stock underlying RSUs granted on July 29, 2024. The sale was automatically executed through a 'sell-to-cover' transaction, as per an irrevocable election by Valamehr, and was not made at his discretion. Following this transaction, Valamehr owns 334,898 shares of common stock. The filing also includes footnotes detailing the range of sale prices and the nature of the transaction.